Dr. Kaley Wilson
Dr. Kaley Wilson is currently the Director of Business Development at Quark Venture, a Vancouver based venture capital group that invests globally in health science. Investing out of the $500M USD Global Health Sciences Fund, Dr. Wilson is responsible for identifying and performing due diligence on potential investment opportunities.
From January 2018 until September 2019, Dr. Wilson was also the CEO of ARTMS Products Inc. a global leader in the development of disruptive medical isotope production technologies. Following its seed financing, Dr. Wilson joined ARTMS to help grow the company and to implement a global sales and marketing strategy.
Dr. Wilson is also an Advisor and Mentor for Ontario Bioscience’s Capital Access Advisory Program (CAPP), a member of GlycoNet’s Commercialization Committee, NMIN’s Research Management Commitee and an Observer on the Boards of Quark Venture’s portfolio companies PHEMI and Canary Medical. Prior to joining Quark Venture in October 2016, Dr. Wilson was Associate Director, Partnerships, at the Centre for Drug Research and Development.
Dr. Wilson obtained her PhD at the University of British Columbia (UBC), Canada, where she worked in close collaboration with senior scientists at INEX Pharmaceuticals on the immunomodulatory activity and vaccine potential of lipid encapsulated nucleic acids. During her Ph.D. Dr Wilson was the recipient of a number of prestigious scholarships and awards including the Doctoral Research Award, Canadian Institutes for Health Research (2005-2008); Trainee Research Award, Michael Smith Foundation for Health Research (2003-2005) and the PGS-A Scholarship, NSERC (2002-2004). Dr. Wilson was also the 2008 recipient of the Gattefosse Canada/Canadian Society for Pharmaceutical Sciences Research Award.